summary
Introduced
07/11/2019
07/11/2019
In Committee
07/11/2019
07/11/2019
Crossed Over
Passed
Dead
12/31/2020
12/31/2020
Introduced Session
116th Congress
Bill Summary
Requires the continued review and approval, as appropriate, of certain pending applications for generic insulin beyond the March 23, 2020, cutoff date previously established by the Food and Drug Administration. Beginning March 23, 2020, these approved generic insulin drugs also are deemed licensed biological products.
AI Summary
This bill, the Affordable Insulin Approvals Now Act, requires the continued review and approval of certain pending applications for generic insulin beyond the March 23, 2020 cutoff date previously established by the Food and Drug Administration (FDA). Beginning on March 23, 2020, any approved generic insulin drugs will be deemed licensed biological products under Section 351 of the Public Health Service Act, even if the review and approval process continues after that date.
Committee Categories
Health and Social Services
Sponsors (17)
Dick Durbin (D)*,
Mike Braun (R),
Sherrod Brown (D),
Shelley Moore Capito (R),
Kevin Cramer (R),
Cory Gardner (R),
John Hoeven (R),
Cindy Hyde-Smith (R),
Doug Jones (D),
Jeff Merkley (D),
Lisa Murkowski (R),
Gary Peters (D),
Mitt Romney (R),
Jeanne Shaheen (D),
Kyrsten Sinema (I),
Tina Smith (D),
Roger Wicker (R),
Last Action
Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text: CR S4809) (on 07/11/2019)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | https://www.congress.gov/bill/116th-congress/senate-bill/2103/all-info |
| BillText | https://www.congress.gov/116/bills/s2103/BILLS-116s2103is.pdf |
| Bill | https://www.congress.gov/116/bills/s2103/BILLS-116s2103is.pdf.pdf |
Loading...